← All trials
NCT05326490
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2022
- Primary completion
- Sep 24, 2024
- Completion date
- Oct 31, 2024
- First posted
- Apr 13, 2022
- Last posted
- Apr 22, 2022
- Enrollment
- 546
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PegBio Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.